ID   LB33-MELA
AC   CVCL_E933
SY   LB33-MEL.A
DR   Wikidata; Q54902059
RX   PubMed=7875194;
RX   PubMed=8566071;
CC   From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium.
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_E934 ! LB33-MELB
OI   CVCL_ZG34 ! LB33-MELC
OI   CVCL_ZG35 ! LB33-MELD
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 29-06-23; Version: 12
//
RX   PubMed=7875194; DOI=10.1002/eji.1830250206;
RA   Lehmann F., Marchand M., Hainaut P., Pouillart P., Sastre-Garau X.,
RA   Ikeda H., Boon T., Coulie P.G.;
RT   "Differences in the antigens recognized by cytolytic T cells on two
RT   successive metastases of a melanoma patient are consistent with immune
RT   selection.";
RL   Eur. J. Immunol. 25:340-347(1995).
//
RX   PubMed=8566071; DOI=10.1002/eji.1830260135;
RA   Brichard V.G., Herman J., Van Pel A., Wildmann C., Gaugler B.,
RA   Wolfel T., Boon T., Lethe B.;
RT   "A tyrosinase nonapeptide presented by HLA-B44 is recognized on a
RT   human melanoma by autologous cytolytic T lymphocytes.";
RL   Eur. J. Immunol. 26:224-230(1996).
//